Under the market change, executive changes have long become the norm
in the pharmaceutical industry.
According to incomplete statistics, since 2022, at least 250 senior executives in the pharmaceutical industry have announced their resignation, including senior executives of multinational pharmaceutical companies in Greater China, management of traditional pharmaceutical companies, and R&D leaders and founders of biopharmaceutical companies
.
It is worth noting that from the current point of view, this wave of executive changes is still continuing, and recently a number of multinational pharmaceutical giants have announced new executive appointments
.
Recently, GSK appointed Julie Brown, former chief financial officer and operating officer of luxury brand Burberry, as the company's chief financial officer, who will join GSK on April 1, 2023, for a one-month handover with the current CFO, and will officially take over as CFO and executive director
of the board of directors on May 1, 2023.
It is understood that Julie Brown, 60, before joining Burberry, she worked in the big health industry for more than 35 years, successively serving as CFO of AstraZeneca and CFO of Xerofer, and served as a non-executive director and audit chairman
of Roche Holdings.
On September 26, the new chief financial officer of dental giant Densch Bercynord Glenn Coleman is also taking office
.
It is worth noting that this year, the people of Denschsbersinode have changed very frequently
.
On April 19, when Denschberg Nord released its first quarter 2022 earnings report, it abruptly announced the dismissal of then-CEO Don Casey without explaining
this rare practice.
John Groetelaars, former CEO of Hillrom, who just joined the board on April 5, was also appointed as interim CEO
.
In addition, on August 25, a month ago, Simon Campion, president of Biddy Global EVP and Biddy Medical, has also become the new CEO of DursberchylNord, effective
September 12.
The industry believes that from the current point of view, with a number of senior executives successively taking office in the company's personnel shock or finally come to an end
.
On September 22, Jingding Pharmaceutical also recently announced the promotion and appointment of two of its senior executives: Peyton Howell will be appointed as the chief operating and growth officer of Jingding Pharmaceutical; Amy McKee, MD, will serve as Chief Medical Officer and Global Head
of the oncology Center of Excellence.
The appointment aims to strengthen the company's medical and scientific focus and continue to maintain record growth through closer alignment between strategy, sales and execution, while improving customer satisfaction and building more repeat customers to maintain a dominant position
in the market in the new phase of drug development transformation.
Ms.
Howell has more than 25 years of leadership experience in the healthcare industry, including multiple leadership positions at AmerisourceBergen, most recently as President of the company's Medical Systems and Specialty Medical Solutions business unit
, which has revenues of up to $50 billion.
Dr.
McKee has nearly 20 years of experience
in FDA regulation, clinical research, benchmark science, and clinical medicine.
As Chief Medical Officer and Global Head of Oncology Center of Excellence, Dr.
McKee will leverage his global medical and scientific leadership to support the implementation
of the company's Phase I to IV clinical trials under a "patient-centric" philosophy.
In general, the departure of senior executives in the pharmaceutical industry, partly for the consideration of personal career development, more reflects the impact of changes in
the industry policy environment and internal structure adjustment on senior executives, from the current hundreds of senior executives to leave, the transformation and upgrading of the pharmaceutical industry at home and abroad, change and innovation and talent flow are obviously accelerating.
